Pan-Cancer Analysis Reveals SKA3 as a Potential Diagnostic and Prognostic Biomarker

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2025-02-25 DOI:10.1111/apm.70009
Chunlin Li, Min Gao, Hua Huang, Nashunbayaer Zha, Gang Guo
{"title":"Pan-Cancer Analysis Reveals SKA3 as a Potential Diagnostic and Prognostic Biomarker","authors":"Chunlin Li,&nbsp;Min Gao,&nbsp;Hua Huang,&nbsp;Nashunbayaer Zha,&nbsp;Gang Guo","doi":"10.1111/apm.70009","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>SKA3, an important factor in cell cycle regulation, is involved in spindle assembly and kinetochore function, playing a critical role in maintaining cancer cell proliferation and division. However, its specific roles and regulatory mechanisms in cancer remain not fully understood. Large-scale datasets from multiple public databases, including The Cancer Genome Atlas and Genotype-Tissue Expression, covering various cancer types, were integrated. Systematic analysis revealed that SKA3 exhibits aberrant expression patterns in multiple cancers and is significantly associated with tumor progression and poor patient prognosis in certain cancers. We explored the status of SKA3 gene mutation, gene amplification and promoter region methylation in various tumors. In the context of immunotherapy, we assessed the value of SKA3 in cancer. Analyzing the correlation between SKA3 expression levels and immune checkpoints and immune cell infiltration, we discovered that SKA3 could serve as a novel immunotherapy biomarker across multiple cancers, guiding clinical immunotherapy decisions. Finally, SKA3 knockdown inhibited lung adenocarcinoma cell proliferation and metastasis. In conclusion, this study provides new insights into the role of SKA3 in cancer and offers significant theoretical and experimental evidence for its development as a diagnostic and prognostic biomarker.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 3","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

SKA3, an important factor in cell cycle regulation, is involved in spindle assembly and kinetochore function, playing a critical role in maintaining cancer cell proliferation and division. However, its specific roles and regulatory mechanisms in cancer remain not fully understood. Large-scale datasets from multiple public databases, including The Cancer Genome Atlas and Genotype-Tissue Expression, covering various cancer types, were integrated. Systematic analysis revealed that SKA3 exhibits aberrant expression patterns in multiple cancers and is significantly associated with tumor progression and poor patient prognosis in certain cancers. We explored the status of SKA3 gene mutation, gene amplification and promoter region methylation in various tumors. In the context of immunotherapy, we assessed the value of SKA3 in cancer. Analyzing the correlation between SKA3 expression levels and immune checkpoints and immune cell infiltration, we discovered that SKA3 could serve as a novel immunotherapy biomarker across multiple cancers, guiding clinical immunotherapy decisions. Finally, SKA3 knockdown inhibited lung adenocarcinoma cell proliferation and metastasis. In conclusion, this study provides new insights into the role of SKA3 in cancer and offers significant theoretical and experimental evidence for its development as a diagnostic and prognostic biomarker.

泛癌症分析发现 SKA3 是一种潜在的诊断和预后生物标记物
SKA3是细胞周期调控的重要因子,参与纺锤体组装和着丝点功能,在维持癌细胞增殖和分裂中起关键作用。然而,其在癌症中的具体作用和调节机制仍未完全了解。整合来自多个公共数据库的大规模数据集,包括癌症基因组图谱和基因型-组织表达,涵盖各种癌症类型。系统分析显示,SKA3在多种癌症中表现出异常表达模式,并且在某些癌症中与肿瘤进展和患者预后不良显著相关。我们探讨了SKA3基因突变、基因扩增和启动子区甲基化在各种肿瘤中的状况。在免疫治疗的背景下,我们评估了SKA3在癌症中的价值。通过分析SKA3表达水平与免疫检查点和免疫细胞浸润的相关性,我们发现SKA3可以作为一种新的免疫治疗生物标志物,跨越多种癌症,指导临床免疫治疗决策。最后,SKA3基因敲低抑制肺腺癌细胞的增殖和转移。总之,本研究为SKA3在癌症中的作用提供了新的见解,并为其作为诊断和预后生物标志物的发展提供了重要的理论和实验证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信